Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tocilizumab
Tocilizumab
Routinely available
SMC (754/12)
28/05/2025
Indication
For the treatment of systemic Juvenile Idiopathic Arthritis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
20mg/ml concentrate for solution for infusion
Comments
Refer to the treatment pathway or local guidelines for preferred formulation.